Our Pricing

Can You Take Orlistat and Mounjaro Together for Weight Loss?

Published: 11 September 2026

Many patients ask whether using orlistat and mounjaro together is safe and effective for weight loss. Combining these two prescription treatments requires careful clinical assessment, as they work through entirely different mechanisms—Mounjaro (tirzepatide) regulates appetite and blood sugar via GLP-1/GIP pathways, while orlistat blocks dietary fat absorption in the gut. Understanding the safety profile, potential benefits, and prescriber requirements is essential before considering combination therapy.

How Orlistat and Mounjaro Together Work in the Body

When considering orlistat and mounjaro together, it's crucial to understand their distinct mechanisms. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist administered as a weekly subcutaneous injection, which reduces appetite, slows gastric emptying, and improves glycaemic control [1]. In the SURMOUNT-1 trial, participants achieved an average weight reduction of 15-20.9% over 72 weeks, depending on dose [1].

Orlistat, conversely, is a lipase inhibitor taken orally three times daily with meals containing fat. It prevents approximately 25-30% of dietary fat from being absorbed through the intestinal wall, instead allowing it to pass through the digestive system [2]. This localised gastrointestinal action means orlistat does not enter systemic circulation in meaningful amounts, which theoretically reduces the risk of pharmacological interaction with Mounjaro's systemic effects.

The combination of orlistat and mounjaro together targets weight loss from two complementary angles: central appetite regulation and peripheral nutrient absorption. However, no large-scale clinical trials have specifically evaluated this dual therapy, so prescribers must assess suitability on an individual basis, considering each patient's medical history, current medications, and weight loss goals.

Is Taking Orlistat and Mounjaro Together Safe?

From a pharmacological perspective, using orlistat and mounjaro together does not present direct drug-drug interactions, as their mechanisms and sites of action differ substantially. Mounjaro acts systemically on incretin receptors, while orlistat functions exclusively within the gastrointestinal tract without significant systemic absorption [2]. The MHRA and prescribing guidelines do not list either medication as a contraindication for the other.

However, combining orlistat and mounjaro together may amplify certain side effects. Both treatments can cause gastrointestinal disturbances—Mounjaro commonly leads to nausea, diarrhoea, and abdominal discomfort, particularly during dose escalation, while orlistat frequently causes oily stools, faecal urgency, and flatulence when dietary fat intake exceeds 15g per meal [3]. The cumulative gastrointestinal burden could prove intolerable for some patients, potentially affecting adherence and quality of life.

Any decision to use orlistat and mounjaro together must be made by a UK-registered prescriber following comprehensive clinical assessment. Patients with a history of chronic gastrointestinal conditions, malabsorption disorders, or those taking medications requiring fat-soluble vitamin absorption should be evaluated with particular caution. Regular monitoring and dose adjustments may be necessary to optimise tolerability and efficacy.

Potential Interaction with Fat-Soluble Vitamins

One important consideration when using orlistat and mounjaro together is the impact on fat-soluble vitamin absorption (A, D, E, K). Orlistat's mechanism inherently reduces dietary fat uptake, which can impair absorption of these essential nutrients [2]. Patients on long-term orlistat therapy are typically advised to take a multivitamin supplement at least two hours before or after orlistat dosing. When combined with Mounjaro's appetite-suppressing effects—which may further reduce overall food intake—the risk of nutritional deficiency could theoretically increase, warranting closer nutritional monitoring and supplementation guidance from your prescriber.

Clinical Rationale for Using Orlistat and Mounjaro Together

Some prescribers may consider orlistat and mounjaro together for patients who have plateaued on monotherapy or require enhanced weight loss to meet clinical targets. Mounjaro delivers substantial weight reduction—up to 20.9% in the highest dose group of the SURMOUNT-1 trial [1]—but individual responses vary. Adding orlistat could theoretically provide an additional 2-3 kg weight loss over six months in patients still consuming moderate-to-high dietary fat [2].

The combination of orlistat and mounjaro together may be particularly relevant for patients with type 2 diabetes and obesity, where Mounjaro addresses both glycaemic control and weight, while orlistat offers a supplementary non-systemic mechanism. However, the incremental benefit must be weighed against increased pill burden, cost, and side effect profile. Most UK prescribers prioritise optimising Mounjaro dose and lifestyle interventions before introducing a second pharmacological agent.

It's essential to note that using orlistat and mounjaro together is considered off-label combination therapy in the UK, as neither medication's Summary of Product Characteristics explicitly endorses concurrent use. This does not preclude prescribing, but it does require informed consent, clear documentation, and ongoing clinical review to ensure safety and appropriateness for each individual patient.

Managing Side Effects When Using Orlistat and Mounjaro Together

Patients taking orlistat and mounjaro together should be prepared for an increased likelihood of gastrointestinal side effects, particularly during the initial weeks of combination therapy. Mounjaro's nausea and diarrhoea typically peak during dose escalation phases and often improve with continued use [1]. Orlistat's gastrointestinal effects—oily spotting, faecal urgency, and flatulence—are directly proportional to dietary fat intake and can be minimised by adhering to a low-fat diet (less than 15g fat per meal) [3].

To optimise tolerability when using orlistat and mounjaro together, prescribers often recommend staggered initiation: stabilising on Mounjaro first (typically 8-12 weeks to reach maintenance dose) before introducing orlistat. This approach allows the body to adapt to Mounjaro's incretin effects and helps distinguish which medication is responsible for any adverse symptoms. Patients should maintain a food and symptom diary to identify triggers and inform dose adjustments.

Hydration is critical when combining orlistat and mounjaro together, as both medications can increase the risk of dehydration—Mounjaro through reduced fluid intake from appetite suppression and gastrointestinal losses, and orlistat through potential diarrhoea. Patients should aim for at least 2 litres of water daily and monitor for signs of dehydration such as dark urine, dizziness, or dry mucous membranes. Any persistent or severe side effects warrant immediate contact with the prescribing clinician.

Dietary Modifications for Combination Therapy

Success with orlistat and mounjaro together depends heavily on dietary adherence. While Mounjaro naturally reduces appetite and caloric intake, patients must also follow a structured low-fat diet to minimise orlistat's gastrointestinal side effects. A balanced macronutrient distribution—approximately 30% of calories from fat, distributed evenly across three main meals—helps optimise both medications' efficacy while maintaining nutritional adequacy. Working with a registered dietitian experienced in weight management pharmacotherapy can significantly improve outcomes and adherence when using this combination approach.

Cost and Accessibility of Orlistat and Mounjaro Together in the UK

The financial consideration of using orlistat and mounjaro together is significant for most patients. At Cured Pharmacy, Mounjaro is available from £124.99 per month (subject to prescriber approval and dose), while orlistat starts from £124.99 for a month's supply [4]. New patients can Save £20 off their first order with code Weightlossnew, bringing the initial monthly cost of combination therapy to approximately £124.99, though this varies based on specific dosing requirements.

When considering orlistat and mounjaro together, patients should also factor in the cost of clinical consultations, blood monitoring (if required for Mounjaro), and nutritional supplementation. While the combined cost exceeds monotherapy, some patients find the enhanced weight loss and metabolic benefits justify the investment, particularly when conventional approaches have proven insufficient. Cured Pharmacy offers transparent upfront pricing and free online consultations under 3 minutes with UK-registered prescribers, ensuring patients understand the full financial commitment before proceeding.

NHS prescribing of orlistat and mounjaro together varies by local formulary and clinical commissioning group policies. Mounjaro is currently licensed for type 2 diabetes in the UK, with weight loss indication approval expanding access. Orlistat may be available on NHS prescription for patients meeting specific BMI criteria (≥30 kg/m², or ≥28 kg/m² with comorbidities). Private prescription through registered online pharmacies like Cured Pharmacy offers greater accessibility for patients who do not meet NHS criteria or prefer expedited service.

Getting a Prescription for Orlistat and Mounjaro Together at Cured Pharmacy

Obtaining a prescription for orlistat and mounjaro together requires clinical assessment by a UK-registered prescriber. At Cured Pharmacy (GPhC 9012511), the process begins with a comprehensive online consultation that evaluates medical history, current medications, weight loss goals, previous treatment responses, and contraindications. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews each case individually to ensure combination therapy is safe and appropriate.

The consultation for orlistat and mounjaro together typically takes under 3 minutes to complete and covers essential safety questions regarding cardiovascular health, gastrointestinal conditions, diabetes status, and concurrent medications. Prescribers will assess whether you meet the clinical criteria for both treatments and determine the appropriate starting doses. For patients new to either medication, a staged approach—initiating one treatment before adding the second—may be recommended to optimise safety and tolerability.

Once approved, Cured Pharmacy dispenses genuine UK-licensed medications in 100% discreet packaging, with delivery typically within 2-3 working days. All treatments come with comprehensive patient information leaflets and access to ongoing pharmacist support via phone (+44 116 4646009) or online messaging. Regular follow-up consultations are essential when using orlistat and mounjaro together, allowing prescribers to monitor progress, adjust doses, manage side effects, and ensure continued appropriateness of combination therapy. You can start your assessment today through our secure online platform, with full transparency on pricing before any commitment.

Monitoring Requirements for Combination Therapy

Patients using orlistat and mounjaro together require more frequent monitoring than those on monotherapy. Initial follow-up is typically recommended at 4 weeks to assess tolerability, adherence, and early weight loss response, followed by reviews every 8-12 weeks. Prescribers will evaluate weight loss trajectory (target: 5% body weight reduction within 3 months), gastrointestinal symptom severity, nutritional status, and any emerging safety concerns. Blood tests may be indicated for patients with diabetes or those at risk of vitamin deficiencies. Treatment should be discontinued if inadequate response occurs despite good adherence, or if side effects outweigh clinical benefits.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 11 September 2026]
2. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. [accessed 11 September 2026]
3. Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ, 335(7631), 1194-1199. [accessed 11 September 2026]
4. Cured Pharmacy. (2025). Weight loss treatments pricing. Cured Pharmacy. [accessed 11 September 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.